Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants

被引:39
作者
Blondino, FE [1 ]
Byron, PR
机构
[1] Baker Norton Pharmaceut Inc, Inhalat Prod Dev, Miami, FL 33137 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharm & Pharmaceut, Aerosol Res Grp, Richmond, VA 23298 USA
关键词
D O I
10.3109/03639049809097273
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The initial water content of a group of 15 pharmaceutically and toxicologically acceptable surfactants showed a tendency to increase with the surfactant hydrophilic-lipophilic balance (HLB) value. Surfactant solubility was determined in chlorine-free "alternative propellants" (n-butane, propane, dimethyl ether [DME], 1,1,1,2-tetrafluoroethane (HFA-134a), and 1,1,1,2,3,3,3-heptafluoropropane [HFA-227ea], and trichloromonofluoromethane [CFC-11] in the absence of cosolvents such as ethanol. Water-soluble surfactants such as Carbowax(R), Sentry(R), PEG 300, Tween(R) 20 and Brij(R) 30 with high HLB values showed appreciable solubility in HFA-134a and HFA-227ea. In systems containing greater than or equal to 80% propellant by weight, each single-phase propellant-surfactant blend was screened for its ability to solubilize iodine and dissolve or solubilize water with increasing surfactant concentration. This screening was performed to investigate the possibility of formulating high-volatility, single-phase systems with increased polarity and solvency from these conventional excipients and vehicles. Ternary-phase diagrams show the regions of apparent single and multiple phase behavior in each system. Despite the increased polarity of the hydrofluoroalkanes (HFAs), appreciable water solubility was seen only with these surfactants in DME and in the hydrocarbons (HCs) n-butane and propane.
引用
收藏
页码:935 / 945
页数:11
相关论文
共 31 条
[1]  
[Anonymous], 1989, MONTR PROT SUBST DEP
[2]  
BOHNENN LJM, 1988, AEROSOL AGE SEP, P26
[3]  
BOULDEN ME, 1992, SPRAY TECH MARKETING, V2, P30
[4]  
BYRON P, 1996, Patent No. 5508023
[5]  
Byron P, 1996, US patent, Patent No. [US 5,492,688, 5492688]
[6]   DRUG-DELIVERY VIA THE RESPIRATORY-TRACT [J].
BYRON, PR ;
PATTON, JS .
JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 1994, 7 (01) :49-75
[7]  
BYRON PR, 1990, RESP DRUG DELIVERY, P167
[8]  
BYRON PR, 1994, RESP DRUG DEL, V4, P231
[9]   COMPARISON OF OUTPUT PARTICLE-SIZE DISTRIBUTIONS FROM PRESSURIZED AEROSOLS FORMULATED AS SOLUTIONS OR SUSPENSIONS [J].
DALBY, RN ;
BYRON, PR .
PHARMACEUTICAL RESEARCH, 1988, 5 (01) :36-39
[10]   DETERMINATION OF DRUG SOLUBILITY IN AEROSOL PROPELLANTS [J].
DALBY, RN ;
PHILLIPS, EM ;
BYRON, PR .
PHARMACEUTICAL RESEARCH, 1991, 8 (09) :1206-1209